

Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/P22563AD7A7EEN.html>

Date: October 2020

Pages: 70

Price: US\$ 3,500.00 (Single User License)

ID: P22563AD7A7EEN

Abstracts

Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2020

SUMMARY

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target constitutes close to 12 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2020, outlays comprehensive information on the Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or is a protein that encodes by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclerosis. PAI-1 is mainly produced by the endothelium and also by other tissue types, such as adipose tissue. PAI-1 inhibits the serine proteases tPA and urokinase and hence inhibit the physiological process that degrades blood clots. PAI-1 inhibits the activity of matrix metalloproteinases (important role in invasion of malignant cells across the basal lamina).

The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 1 and 1 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 7 molecules, respectively. Report covers products from therapy areas Respiratory, Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Infectious

Disease, Genetic Disorders, Metabolic Disorders and Undisclosed which include indications Arterial Thrombosis, Coronavirus Disease 2019 (COVID-19), Idiopathic Pulmonary Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Renal Failure, Acute Respiratory Distress Syndrome, Alpha-1 Antitrypsin Deficiency (A1AD), Breast Cancer, Central Nervous System (CNS) Tumor, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Emphysema, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hepatocellular Carcinoma, Inflammatory Bowel Disease, Interstitial Lung Fibrosis, Melanoma, Metastatic Lung Cancer, Multiple Sclerosis, Neuromyelitis Optica (Devic's Syndrome), Neurotoxicity Syndromes, Non-Small Cell Lung Cancer, Obesity, Pediatric Diffuse Intrinsic Pontine Glioma, Pneumonia, Solid Tumor, Stroke, Systemic Sclerosis (Scleroderma), Thromboembolism, Thrombosis, Unspecified and Venous (Vein) Thrombosis.

Furthermore, this report also reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)

The report reviews Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which

includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics and enlists all their major and minor projects

The report assesses Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Overview

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Companies Involved in Therapeutics Development

Accendatech Au Pty Ltd

Beam Therapeutics Inc

Jazz Pharmaceuticals Plc

MDI Therapeutics Inc

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Drug Profiles

ACT-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

defibrotide sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate SERPINA1 for Alpha-1 Antitrypsin Deficiency - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDI-2268 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDI-2517 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SK-216 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-5275 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-5441 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-5484 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-5614 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1)

or SERPINE1) - Dormant Products

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Discontinued Products

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Product Development Milestones

Featured News & Press Releases

May 14, 2020: Jazz Pharmaceuticals announces presentation on Defitelio at Virtual EHA 2020 Meeting

Apr 29, 2020: Jazz Pharmaceuticals stops enrollment in phase 3 study evaluating Defibrotide for the prevention of Venous Occlusive Disease

Nov 07, 2019: Jazz Pharmaceuticals to present abstracts on Defitelio (defibrotide sodium) at ASH 2019 Annual Meeting

Oct 10, 2019: Jazz Pharmaceuticals announces first patient enrolled in phase 2 clinical trial evaluating defibrotide for the prevention of CAR-T Associated Neurotoxicity

Sep 04, 2019: Launch of Defitelio injection 200mg for the treatment of sinusoidal obstruction syndrome (hepatic veno-occlusive disease)

Jun 18, 2019: Marketing approval of Defitelio by MHLW for the treatment of sinusoidal obstruction syndrome / hepatic veno-occlusive disease

May 16, 2019: Jazz Pharmaceuticals to present new data on defitelio at upcoming EHA Congress

Mar 25, 2019: Experimental drug reverses high cholesterol, obesity-related nonalcoholic fatty liver disease in animals

Nov 28, 2018: Jazz Pharmaceuticals to present data on Defitelio at ASH 2018 Annual Meeting

Oct 17, 2018: New Drug Application Filed for defibrotide sodium

Sep 19, 2018: Nippon Shinyaku announces orphan drug designation granted to NS-73

Sep 19, 2018: Nippon Shinyaku: Orphan drug designation granted to NS-73

Feb 23, 2018: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease

Nov 01, 2017: Jazz Pharmaceuticals to Present Abstracts on Defitelio at ASH 2017 Annual Meeting

Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients

Appendix

Methodology

Coverage

Secondary Research

[Primary Research](#)
[Expert Panel Validation](#)
[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Accendatech Au Pty Ltd, H2 2020
Pipeline by Beam Therapeutics Inc, H2 2020
Pipeline by Jazz Pharmaceuticals Plc, H2 2020
Pipeline by MDI Therapeutics Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

I would like to order

Product name: Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/P22563AD7A7EEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P22563AD7A7EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970